Table 1.
Phenotype Improvement(s) | Model | Virus(es) | Reference(s) |
---|---|---|---|
Increased cytokine producing virus-specific CD4/CD8 (IFN-γ, TNF-α, IL-2); improved antiviral responses | HIV, LCMV | [12,13,23,26,34] | |
Reduced expression of PD-1, TIM-3, TIGIT, BATF, CD160 on CD8 (decreased cell exhaustion) | HIV | [12,34] | |
Reduced KI67+ population in CD4/CD8; decrease of HIV-mediated T-cell hyperactivation | HIV | [12] | |
Reduced HLA-DR, CD38, CD69, CD80 expression in CD4/CD8; decrease of HIV-mediated T-cell hyperactivation | HIV | [12,34,41*,53*] | |
Decrease of caspase-3-dependent apoptosis in total and specific CD4 T-cells | HIV, LCMV | [13,54,55*] | |
Accelerating neutralizing Abs production | LCMV | [18] | |
Reduced PD-L1 and IL-10 expression in DCs, mono and macro. Decreased IL-10 levels in plasma/sera | HIV, LCMV | [23,26,41*] | |
Reduced IL-1 and IL-18 levels, and inflammasome activation in DCs and monos; decreased CD80 expression in monos | HIV, LCMV | [23,26,41*] | |
Increase of splenocyte cell numbers (DCs, macrophages, CD4, CD8, B and matural killers) | LCMV | [23,26,52] | |
Proper splenic architecture organization | LCMV | [23,26] | |
Decreased CXCR4 expression on GC B Increased levels of specific Ab production and specific ASCs | LCMV | [52] | |
Decreased caspase-3+ apoptotic virus-specific GC B (by counteracting plasmablast differentiation); B expansion | LCMV | [54] | |
Increased virus-specific B number; Decreased CTL CD8-mediated kill of specific B | LCMV | [56] | |
Reduced TRAIL/DR5-mediated apoptosis in CD4 | HIV | [55*] | |
Decreased % of TRAIL+ and apoptotic CD4 | HIV | [57] | |
Increased Fas-mediated apoptosis in CD4 and CD8 T-cells | HIV | [58*] | |
Increased expression of BTLA on CD4 T-cells; reduced hyper-immune activation | HIV | [59*] | |
Increased Th1 differentiation in late primed virus-specific CD4 | LCMV | [60] |
: Humans; : Humanized mice; ; Mice; *: in vitro viral infection; ASC: antibody-secreting cells; CD: cluster of Differentiation; TNF: tumor Necrosis Factor; IL: interleukin; PD: programmed Death Protein; TIM: T-cell Immunoglobulin and Mucin; TIGIT: T-cell Ig and ITIM domain; BATF: basic leucine zipper transcription factor ATF-like; LCMV: Lymphocytic choriomeningitis virus; KI: proliferation Marker, Ki-67 is a prototype monoclonal Ab and was first produced in Kiel, Germany; HLA-DR: human leukocyte antigen - antigen D related; DCs: dendritic cells; CXCR: C-X-C motif chemokine receptor; GC: germinal center; ASCs: antibody secreting cells; CTL: cytotoxic T lymphocytes; TRAIL: TNF-related apoptosis inducing ligand; Th1: Type I T helper cells; BTLA: B and T lymphocyte attenuator.